< Back to previous page


ReLACT: Intranasal probiotics against respiratory viral infections.

Respiratory Syncytial Virus (RSV) is the leading cause of severe lower respiratory disease in young children worldwide. Nearly all children are exposed to RSV by the age of 2, approximately 40 % will develop a lower respiratory tract infection such as bronchiolitis and up to 10 % of these children require hospitalization. Severe inflammation is a typical hallmark of the hospitalized children. Despite the discovery of the virus in 1956, prevention and treatment options for RSV are limited. In this project, an innovative approach based on the intranasal application of specific probiotic strains is explored to prevent the severe lung inflammation that follows the acute infection. We will investigate whether delivery of intranasal probiotics prior to RSV infection can prevent the development of severe RSV disease by functioning as immunomodulatory agents that can reduce RSV-associated inflammation. Furthermore, we will test if delivery of an RSV vaccine together with intranasal probiotics enhances both safety and efficacy of this vaccine.
Date:1 Oct 2019  →  31 Dec 2020
Disciplines:Infectious diseases, Vaccinology